期刊文献+
共找到1,139篇文章
< 1 2 57 >
每页显示 20 50 100
Carrimycin in the treatment of acute promyelocytic leukemia combined with pulmonary tuberculosis: A case report
1
作者 Fu-Yu Yang Lei Shao +1 位作者 Jie Su Zhen-Meng Zhang 《World Journal of Clinical Cases》 SCIE 2024年第3期623-629,共7页
BACKGROUND Pulmonary tuberculosis(PTB)is prevalent in immunocompromised populations,including patients with hematologic malignancies,human immunodeficiency virus infections,and chronic diseases.Effective treatment for... BACKGROUND Pulmonary tuberculosis(PTB)is prevalent in immunocompromised populations,including patients with hematologic malignancies,human immunodeficiency virus infections,and chronic diseases.Effective treatment for acute promyelocytic leukemia(APL)combined with PTB is lacking.These patients show an extremely poor prognosis.Therefore,studies should establish efficient treatment options to improve patient survival and prognosis.CASE SUMMARY A 60-year-old male with pain in the right side of his chest and a fever for 4 d visited the outpatient department of our hospital.Peripheral blood smear revealed 54%blasts.Following bone marrow examinations,variant APL with TNRC18-RARA fusion gene was diagnosed.Chest computed tomography scan showed bilateral pneumonitis with bilateral pleural effusions,partial atelectasis in the lower lobes of both lungs,and the bronchoalveolar lavage fluid gene X-Pert test was positive,indicative of PTB.Carrimycin,ethambutol(EMB),and isoniazid(INH)were administered since he could not receive chemotherapy as the WBC count decreased continuously.After one week of treatment with carrimycin,the patient recovered from fever and received chemotherapy.Chemotherapy was very effective and his white blood cells counts got back to normal.After being given five months with rifampin,EMB and INH and chemotherapy,the patient showed complete remission from pneumonia and APL.CONCLUSION We report a case of PTB treated successfully with carrimycin with APL that requires chemotherapy. 展开更多
关键词 Carrimycin Hematologic disease acute myeloid leukemia acute promyelocytic leukemia Pulmonary tuberculosis Case report
下载PDF
CD71-mediated liposomal arsenic-nickel complex combined with all-trans retinoic acid for the efficacy of acute promyelocytic leukemia
2
作者 Xiao Liu Lili Zhang +7 位作者 Yueying Yang Weiwei Yin Yunhu Liu Chunyi Luo Ruizhe Zhang Zhiguo Long Yanyan Jiang Bing Wang 《Asian Journal of Pharmaceutical Sciences》 SCIE CAS 2023年第4期80-95,共16页
Clinically,arsenic trioxide(ATO)was applied to the treatment of acute promyelocytic leukemia(APL)as a reliable and effective frontline drug.However,the administration regimen of AsⅢwas limited due to its fast clearan... Clinically,arsenic trioxide(ATO)was applied to the treatment of acute promyelocytic leukemia(APL)as a reliable and effective frontline drug.However,the administration regimen of AsⅢwas limited due to its fast clearance,short therapeutic window and toxicity as well.Based on CD71 overexpressed on APL cells,in present study,a transferrin(Tf)-modified liposome(LP)was established firstly to encapsulate AsⅢin arsenic-nickel complex by nickel acetate gradient method.The AsⅢ-loaded liposomes(AsLP)exhibited the feature of acid-sensitive release in vitro.Tf-modified AsLP(Tf-AsLP)were specifically taken up by APL cells and the acidic intracellular environment triggered liposome to release AsⅢwhich stimulated reactive oxygen species level and caspase-3 activity.Tf-AsLP prolonged half-life of AsⅢin blood circulation,lowered systemic toxicity,and promoted apoptosis and induced cell differentiation at lesion site in vivo.Considering that ATO combined with RA is usually applied as the first choice in clinic for APL treatment to improve the therapeutic effect,accordingly,a Tf-modified RA liposome(Tf-RALP)was designed to reduce the severe side effects of free RA and assist Tf-AsLP for better efficacy.As expected,the tumor inhibition rate of Tf-AsLP was improved significantly with the combination of Tf-RALP on subcutaneous tumor model.Furthermore,APL orthotopic NOD/SCID mice model was established by 60CO irradiation and HL-60 cells intravenously injection.The effect of co-administration(Tf-AsLP+Tf-RALP)was also confirmed to conspicuous decrease the number of leukemia cells in the circulatory system and prolong the survival time of APL mice by promoting the APL cells’apoptosis and differentiation in peripheral blood and bone marrow.Collectively,Tf-modified acid-sensitive AsLP could greatly reduce the systemic toxicity of free drug.Moreover,Tf-AsLP combined with Tf-RALP could achieve better efficacy.Thus,transferrinmodified AsⅢliposome would be a novel clinical strategy to improve patient compliance,with promising translation prospects. 展开更多
关键词 TRANSFERRIN Arsenic trioxide acute promyelocytic leukemia All-trans retinoic acid LIPOSOME
下载PDF
Atypical Hemolytic Uremic Syndrome in a Patient with Acute Promyelocytic Leukemia: A Case Report
3
作者 Pilar Dutari Tantrantan Leonce Adjoumani +3 位作者 Marilyne Grinand Olivier Lavelle Moglie Le Quintrec Safia Chebrek 《Case Reports in Clinical Medicine》 2023年第2期37-43,共7页
Introduction: Acute Promyelocytic Leukemia (APL) is highly associated with hemostasis alterations. The atypical hemolytic uremic syndrome (aHUS) is a rare type of Thrombotic Microangiopathy (TMA) due to an overactivat... Introduction: Acute Promyelocytic Leukemia (APL) is highly associated with hemostasis alterations. The atypical hemolytic uremic syndrome (aHUS) is a rare type of Thrombotic Microangiopathy (TMA) due to an overactivation of the alternative complement pathway. Case Presentation: A 48-years-old woman was diagnosed with APL and achieved molecular remission after induction therapy. During the second consolidation cycle she presented with TMA. She began treatment with plasma exchange plus corticotherapy but due to aggravation of symptoms Eculizumab was initiated. Thrombotic thrombocytopenic purpura, infections and drug toxicity causes were ruled out. There was no evidence of relapse of the APL. Genetic studies of the hereditary anomalies of the alternative complement pathway were negative and the decision of stopping Eculizumab was made. During maintenance therapy for the APL she presented a severe relapse of the aHUS, requiring dialysis. She re-started treatment with Eculizumab with a progressive hematologic recovery and improvement of renal function. She completed APL treatment without relapse of the leukemia for the moment and continues to be treated with Eculizumab. Conclusion: This is the first published case of coexisting aHUS and APL successfully treated with Eculizumab. 展开更多
关键词 Atypical Hemolytic Uremic Syndrome acute promyelocytic leukemia
下载PDF
MOLECULAR CHARACTERIZATION OF THE CHROMOSOME TRANSLOCATION T (15; 17) IN ACUTE PROMYELOCYTIC LEUKEMIA (APL)
4
作者 陈赛娟 童建华 +6 位作者 董硕 耿解萍 黄薇 曹琪 孙关林 王振义 陈竺 《Medical Bulletin of Shanghai Jiaotong University》 CAS 1992年第2期1-16,共16页
Acute promyelocytic leukemia (APL) represents the first example o f a human cancer successfully treated with a differentiation reducer, all-trans retinoic acid. APL is also characterized by a specific chromosome trans... Acute promyelocytic leukemia (APL) represents the first example o f a human cancer successfully treated with a differentiation reducer, all-trans retinoic acid. APL is also characterized by a specific chromosome translocution t (15; 17). In this work, using techniques of molecular biology, we demonstrated that the gene coding for the retinoic acid receptor alpha (RARA), normally located on chromosome 17, was disrupted by the t (15; 17) and fused with the PML gene on chromosome 15. The chromosome 17 breaks were mapped consistently within the second intron of the RARA gene while the chromosome 15 breaks were clustered in two limited regions within the PML gene. Molecular cloning and sequence analysis of part of the PML gene allowed to establish a specific "nested" reverse transcription/polymerase chain reaction (PCR) procedure to characterize the expression patterns of the PML-RARA fusion gene. Different iso forms of the fusion transcripts were discovered which were produced as a result of distinct PML gene rearrangements. The biological activity of the PML-RARA fusion gene and its iso forms should be further explored. 展开更多
关键词 acute promyelocytic leukemia (apl) chromosome TRANSLOCATION RARA GENE PML GENE
下载PDF
Secondary acute promyelocytic leukemia following chemotherapy for gastric cancer: A case report 被引量:2
5
作者 Ying-Cheng Zhang Yu-Qi Zhou +7 位作者 Bing Yan Jun Shi Li-Juan Xiu Yu-Wei Sun Xuan Liu Zhi-Feng Qin Pin-Kang Wei Yong-Jin Li 《World Journal of Gastroenterology》 SCIE CAS 2015年第14期4402-4407,共6页
Therapy-related acute myeloid leukemia(t-AML) refers to a heterogeneous group of myeloid neoplasms that develop in patients following extensive exposure to either cytotoxic agents or radiation.The development of t-AML... Therapy-related acute myeloid leukemia(t-AML) refers to a heterogeneous group of myeloid neoplasms that develop in patients following extensive exposure to either cytotoxic agents or radiation.The development of t-AML has been reported following treatment of cancers ranging from hematological malignancies to solid tumors; however, to our knowledge, t-AML has never been reported following treatment of gastric cancer.In this study, we report the development of t-acute promyelocytic leukemia in a cT 4N1M0 gastric cancer patient after an approximate 44 mo latency period following treatment with 4 cycles of oxaliplatin(OXP)(85 mg/m2 on day 1) plus capecitabine(1250 mg/m2 orally twice daily on days 1-14) in combination with recombinant human granulocyte-colony stimulating factor treatment.Karyotype analysis of the patient revealed 46,XY,t(15;17)(q22;q21)[15]/46,idem,-9,+add(9)(p22)[2]/46,XY[3], which, according to previous studies, includes some "favorable" genetic abnormalities.The patient was then treated with all-trans retinoic acid(ATRA, 25 mg/m2/d) plus arsenic trioxide(ATO, 10 mg/d) and attained complete remission.Our case illuminated the role of certain cytotoxic agents in the induction of t-AML following gastric cancer treatment.We recommend instituting a mandatory additional evaluation for patients undergoing these therapies in the future. 展开更多
关键词 GASTRIC cancer acute promyelocytic leukemia Oxalip
下载PDF
LEUKOCYTOSIS AND RETINOIC ACID SYNDROME IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA TREATED WITH ARSENIC TRIOXIDE 被引量:4
6
作者 Bo Jin Ke-zuo Hou Yun-peng Liu Ping Yu 《Chinese Medical Sciences Journal》 CAS CSCD 2006年第3期171-174,共4页
Objective To study the incidence of leukocytosis and retinoic acid (RA) syndrome in newly diagnosed and relapsed acute promyelocytic leukemia (APL) patients treated with arsenic trioxide (ATO). Methods Thirty pa... Objective To study the incidence of leukocytosis and retinoic acid (RA) syndrome in newly diagnosed and relapsed acute promyelocytic leukemia (APL) patients treated with arsenic trioxide (ATO). Methods Thirty patients with newly diagnosed or relapsed APL received ATO for remission induction at the dose of 10 mg/d. RA syndrome was defined when patient was with one or more of the following signs or symptoms: fever, dyspnea, serous cavity effusion, muscular pain, pulmonary infiltration, weight gain, or pulmonary infiltration on chest X-ray. Results Twenty-three (77%) patients achieved complete remission, mean time to remission was 37. 1 days. Leukocytosis was observed in 14 (47%) patients, mean time to leukocytosis was 12. 7 days, median baseline leukocyte count for patients with leukocytosis was 3.1 x 109/L, which was higher than that for patients who did not de,.'elop leukocytosis (2.6 × 10^9/L, z = - 2. 635, P = 0. 008). No other cytotoxic therapy was administered, and the leukocytosis resolved in all cases. The RA syndrome was observed in 9 (30%) patients, mean time to diagnose of RA syndrome was 13.9 days, median baseline leukocyte count for patients with RA syndrome was 3.6 × 10^9/L, which was higher than that for patients who did not develop RA syndrome (2. 6 × 10^9/L, z = - 1. 909, P =0. 046). No patient died of RA syndrome. Conclusion Leukocytosis and RA syndrome are associated with ATO and baseline leukocyte count respectively, and there is distinct link between leukocytosis and RA syndrome. 展开更多
关键词 arsenic trioxide acute promyelocytic leukemia LEUKOCYTOSIS retinoic acid syndrome
下载PDF
Sweet syndrome and differentiation syndrome in a patient with acute promyelocytic leukemia 被引量:1
7
作者 Guillermo Solano-López Mar Llamas-Velasco +1 位作者 Maria José Concha-Garzón Esteban Daudén 《World Journal of Clinical Cases》 SCIE 2015年第2期196-198,共3页
The differentiation syndrome is an inflammatory reaction with increased capillary permeability that occurs in up to 25% of patients with acute promyelocytic leukemia treated with all-trans retinoic acid. A 50-year-old... The differentiation syndrome is an inflammatory reaction with increased capillary permeability that occurs in up to 25% of patients with acute promyelocytic leukemia treated with all-trans retinoic acid. A 50-year-old man with acute promyelocytic leukemia underwent chemotherapy with idarubicin and all-trans retinoic acid. On day +21 the patient developed pruritic prepatelar papules as well as several 10 mm subcutaneous nodules in both thighs accompanied by persistent fever. On the day +25 the patient presented with bilateral pulmonary crackles, infiltrates in the right lower lobe and severe hypotension which required dopamine infusion. Biopsy of one of the thighs nodules was performed. A Sweet syndrome associated to a differentiation syndrome was suspected. All-trans retinoic acid therapy was discontinued and dexamethasone was administered. In 48 h the patient showed remission of the fever and the infiltrates and the skin lesions acquired a residual aspect. It is debatable whether these two syndromes are distinct entities with common mechanisms or whether they are poles of the same spectrum. Dermatologists and hematologists must be aware of these two syndromes and its pathophysiologic association. 展开更多
关键词 Differentiation SYNDROME SWEET SYNDROME acute promyelocytic leukemia ALL-TRANS RETINOIC acid
下载PDF
In vitro study on arsenic sulfide (realgar)-induced apoptosis of retinoic acid susceptible or resistant acute promyelocytic leukemia cell lines 被引量:3
8
作者 陈思宇 刘陕西 李信民 《Journal of Medical Colleges of PLA(China)》 CAS 2002年第1期34-38,共5页
Objective: To further understand the possible mechanisms of arsenic sulfide (realgar) in the treatment of acute promyelocytic leukemia (APL). Methods: All-trans retinoic acid (ATRA)-susceptible APL cell line (NB4 cell... Objective: To further understand the possible mechanisms of arsenic sulfide (realgar) in the treatment of acute promyelocytic leukemia (APL). Methods: All-trans retinoic acid (ATRA)-susceptible APL cell line (NB4 cells) and ATRA-resistant APL cell line (MR2 subclone) were used as models in vitro. At various times after incubated with various concentrations of realgar, NB4 and MR2 cells were observed by cell viability , cell proliferation and cell morphology; cell cycle and the expression of Annexin V were assayed by flow cytometry. Results: Cell viability and proliferation of NB4 and MR2 cells were inhibited after the treatment, to some extent, in a dose and time dependent manner. 177 - 711g/L of realgar treated NB4 and MR2 cell presented morphologically some features of apoptotic cells such as intact cell membrane, chromatin condensation and nuclear fragmentation, apoptosis body could be found by electron microscopy as well. Sub-Gl cells and cell cycle arrest were observed by flow cytometry. The proportion of Annexin V -FITC+/PI cells , which represent apoptotic cells, was up-regulated. Conclusion: Realgar could induce apoptosis of acute promyelocytic leukemia cell despite its susceptibility to retinoic acid in the way that may be different from retinoic acid. 展开更多
关键词 arsenic sulfide apoptosis leukemia promyelocytic acute
下载PDF
All-trans Retinoic Acid,Arsenic Trioxide,and Anthracycline-based Chemotherapy Improves Outcome in Newly Diagnosed Acute Promyelocytic Leukemia Regardless of FLT3-ITD Mutation Status 被引量:2
9
作者 Lin-wei XU Yong-zhong SU Hong-fang TAO 《Current Medical Science》 SCIE CAS 2021年第3期491-497,共7页
All-trans retinoic acid(ATRA)and pre-upfront arsenic trioxide(ATO)have revolutionized the therapy of acute promyelocytic leukemia(APL).However,internal tandem duplication of FMS-like tyrosine kinase 3(FLT3-ITD)mutatio... All-trans retinoic acid(ATRA)and pre-upfront arsenic trioxide(ATO)have revolutionized the therapy of acute promyelocytic leukemia(APL).However,internal tandem duplication of FMS-like tyrosine kinase 3(FLT3-ITD)mutations is associated with increased risk of relapse.The aim of this study was to analyze the prognostic impact of FLT3-ITD on APL patients who received remission induction with ATRA,idarubicin(IDA)and/or ATO,followed by ATRA plus ATO along with anthracycline,as consolidation therapy.A total of 72 patients newly diagnosed with APL were included in this study.83.3%of the patients achieved complete remission(CR)after induction therapy.FLT3-ITD mutations were detected in 16(22.2%)patients and closely related to bcr-3 PML-RARa transcript(P<0.001).The 5-year overall survival(OS)rate was 100%in both FLT3-ITDposltlve and FLT3-ITD^(negatlve)groups,and there was no significant difference in 5-year event-free survival(EFS)between the two groups(78.3%vs.83.3%,P=0.85).ATRA plus ATO and anthracycline-based chemotherapy achieved great outcome in newly diagnosed APL regardless of the FLT3-ITD mutation status. 展开更多
关键词 all-trans retinoic acid acute promyelocytic leukemia arsenic trioxide ANTHRACYCLINE internal tandem duplication of FMS-like tyrosine kinase 3
下载PDF
Successful treatment of relapsed acute promyelocytic leukemia with arsenic trioxide in a hemodialysis-dependent patient: A case report 被引量:1
10
作者 Hee Jeong Lee Sang-Gon Park 《World Journal of Clinical Cases》 SCIE 2020年第21期5347-5352,共6页
BACKGROUND Arsenic trioxide(ATO)is recommended for patients who do not achieve molecular remission or who have molecular or morphologic relapse.However,there are no guidelines for adjusting ATO dosage in patients with... BACKGROUND Arsenic trioxide(ATO)is recommended for patients who do not achieve molecular remission or who have molecular or morphologic relapse.However,there are no guidelines for adjusting ATO dosage in patients with severe renal failure or on dialysis.Herein,we report the successful treatment of relapsed acute promyelocytic leukemia(APL)in a patient on hemodialysis with ATO single agent and review the cases in literature.CASE SUMMARY A 46-year-old woman who has been on hemodialysis to chronic glomerulonephritis for 15 years visited our hospital for pancytopenia.She had been seen for pancytopenia 3 years ago and had been diagnosed with APL.She also received chemotherapy for APL but unfortunately was lost to follow-up after her second consolidation chemotherapy.She was noted to have pancytopenia by her nephrologist during hemodialysis 1 mo ago.Bone marrow biopsy and reverse transcriptase-polymerase chain reaction(RT-PCR)tests revealed a diagnosis of relapsed APL.Treatment for relapsed APL with ATO single agent was started and she achieved molecular remission after administering 24 doses of ATO.Thus far,four consolidation therapies have been performed with the ATO single agent,and,to date,the molecular remission has been maintained as negative promyelocytic leukemia/retinoic acid receptor-αfusion gene as confirmed by RTPCR testing for two years.CONCLUSION This is a rare case of relapsed APL successfully treated with the single agent ATO in a patient on hemodialysis. 展开更多
关键词 Arsenic trioxide acute promyelocytic leukemia PANCYTOPENIA HEMODIALYSIS promyelocytic leukemia/retinoic acid receptor-αfusion gene Case report
下载PDF
REPEATED ARSENIC TRIOXIDE INTRAVENOUS INFUSION CAUSES FOCAL BONE MARROW NECROSIS IN TWO ACUTE PROMYELOCYTIC LEUKEMIA PATIENTS 被引量:1
11
作者 JinZhou RanMeng +1 位作者 Xin-huaSui Bao-fengYang 《Chinese Medical Sciences Journal》 CAS CSCD 2004年第4期281-281,共1页
关键词 Adult Antineoplastic Agents ARSENICALS Bone Marrow Bone Marrow Diseases Child Female Humans Infusions Intravenous leukemia promyelocytic acute Male NECROSIS Oxides
下载PDF
Myeloid sarcoma of the colon as initial presentation in acute promyelocytic leukemia:A case report and review of the literature 被引量:1
12
作者 Lei Wang Da-Li Cai Na Lin 《World Journal of Clinical Cases》 SCIE 2021年第21期6017-6025,共9页
BACKGROUND Myeloid sarcoma(MS)rarely occurs in acute promyelocytic leukemia(APL)at onset,but it can develop in relapse cases,especially after APL treated with alltrans retinoic acid(ATRA).Therefore little is known abo... BACKGROUND Myeloid sarcoma(MS)rarely occurs in acute promyelocytic leukemia(APL)at onset,but it can develop in relapse cases,especially after APL treated with alltrans retinoic acid(ATRA).Therefore little is known about the clinical features and suitable treatment for APL related MS due to the rarity of the disease,although this may be different from the treatment and prognosis of MS in the relapse stage.To our best knowledge,this is the second case report of APL initial presentation as colon MS.CASE SUMMARY A 77-year-old woman complained of intermittent right lower abdominal pain,black stool,and difficult defecation for 2 mo.Physical examination showed diffuse tenderness during deep palpation and an anemic appearance.Laboratory findings showed positivity for fecal occult blood testing;white blood cell count:3.84×109/L;hemoglobin:105 g/L;platelet count:174×109/L;and negativity for tumor markers.Abdominal enhanced computed tomography showed a space occupying lesion in the colon(1.9 cm).Fibrocolonoscopy revealed a polypoid and ulcerated mass measuring 2.5 cm.The tumor was removed.To our surprise,MS was confirmed by immunohistochemistry.PML/RARαfusion gene was detected in colon specimens by fluorescent in situ hybridization and real-time reverse transcription polymerase chain reaction,which was consistent with the bone marrow.She was diagnosed as having APL related MS.A smooth and unobstructed intestinal wall was found by fibrocolonoscopy,and continuous molecular remission was confirmed in both the bone marrow and colon after four courses of ATRA+arsenic trioxide(ATO).ATRA+ATO showed a favorable therapeutic response for both APL and MS.CONCLUSION Early use of ATRA can benefit APL patients,regardless of whether MS is the first or recurrent manifestation. 展开更多
关键词 acute promyelocytic leukemia Myeloid sarcoma All-trans retinoic acid Extramedullary disease COLON Fluorescent in situ hybridization Case report
下载PDF
Relationship between hydrogen sulfide and inflammation in patients with acute promyelocytic leukemia complicated with infection 被引量:1
13
作者 Ling Fan Li-Feng Chen +2 位作者 Jing Fan Ling Zhang Li-Rong Guo 《Journal of Hainan Medical University》 2017年第6期65-67,共3页
Objective:To investigate the clinical effect of hydrogen sulfide on acute promyelocytic leukemia (acute promyelocytic leukemia APL) complicated with infection.Methods: A total of 30 cases patients of APL complicated w... Objective:To investigate the clinical effect of hydrogen sulfide on acute promyelocytic leukemia (acute promyelocytic leukemia APL) complicated with infection.Methods: A total of 30 cases patients of APL complicated with infection were selected as experimental group, 26 cases patients with only APL as control group. Detect the H2S, C-reactive protein (CRP), tumor necrosis factor alpha (TNF-α), interleukin-1 beta (IL-1β) and interleukin-10 (IL-10) level in the blood of the experimental group and control group, comparing the above indicators have no significant difference between the two groups.Results: Experimental group of blood H2S, CRP, TNF-α and IL-1β levels were significantly increased, IL-10 decreased, which was statistically significant compared with the control group;the H2S, CRP, TNF-αand IL-1βlevels of the experimental group after the treatment were significantly decreased, IL-10 level increased, There was statistical significance compared with the experimental group before the treatment;compared with the control group, the difference was not statistically significant. The experimental group H2S was positively correlated with CRP, TNF-α and IL-1β, H2S was negatively correlated with IL-10.Conclusions: Endogenous H2S is involved in the pathophysiological process of inflammation in APL with infection, and its role may be similar to that of CRP, TNF-α and IL-1β, which is contrary to the effect of IL-10. 展开更多
关键词 acute promyelocytic leukemia Hydrogen SULFIDE INFLAMMATION
下载PDF
Distribution and clonality of peripheral blood TCR Vα subfamily T cells in patients with acute promyelocytic leukemia
14
作者 Dongzhi Cen Yangqiu Li Shaohua Chen Lijian Yang Zhi Yu 《The Chinese-German Journal of Clinical Oncology》 CAS 2007年第6期591-593,共3页
Objective: To investigate the distribution and clonality of TCR Va subfamily T cells in patients with acute promyelocytic leukemia (APL). Methods: The complementary determining region 3 (CDR3) of TCR Va 29 subfa... Objective: To investigate the distribution and clonality of TCR Va subfamily T cells in patients with acute promyelocytic leukemia (APL). Methods: The complementary determining region 3 (CDR3) of TCR Va 29 subfamily genes in peripheral blood mononuclear cells from 9 APL patients were amplified using RT-PCR. The positive products were further analyzed to identity the clonality of T cells by GeneScan technique. Results: One to seven of TCR Va subfamilies could be detected in peripheral blood T cells from 9 cases with APL, the frequent expression of Va subfamilies predominated in Vα3 and Va19. Clonal expanded T cells could be detected in 8 APL patients, which predominant used Va3, Va26 or Va27 (3 out of 8 cases). However, almost all Va subfamilies with polyclonal expansion could be detected in peripheral blood T cells from 10 cases of normal individuals. Conclusion: Remarkable skew distribution and clonal expansion of TCR Va subfamilies T cells is the common feature in patients with APL. Clonal expansion of T cells might reflect a response in host to APL cell associated antigen, whether these expanded T cells have the ability for specific cytotoxicity against APL cells, remains an open question. 展开更多
关键词 acute promyelocytic leukemia (apl TCR Va gene CLONALITY
下载PDF
CYTOKINE SECRETION IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA AFTER TREATMENT WITH ALLTRANS RETINOIC ACID
15
作者 姜国胜 唐天华 +10 位作者 毕可红 张玉昆 任海泉 姜枫勤 任青华 真刚 刘传芳 彭军 郭桂月 刘秀兰 田志刚 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2003年第1期33-37,共5页
ABSRTACT Objective: To detect the modulation of cytokines production by acute promyelocytic leukemia (APL) cells before or after exposure to all-trans retinoic acid (ATRA). Methods: Diagnoses were performed according... ABSRTACT Objective: To detect the modulation of cytokines production by acute promyelocytic leukemia (APL) cells before or after exposure to all-trans retinoic acid (ATRA). Methods: Diagnoses were performed according to the FAB cytological classification criteria and cytogenetic criteria. Bone marrow or blood samples from APL patients were collected in heparinized microfuge tube. Primary APL cells were separated and purified by traditional Ficoll-Hypaque density centrifugation and enriched after adherence to plastic surfaces. IL-1b, IL-6, IL-8, TNFa and G-CSF levels in the supernatants of cultured leukemia cells were estimated by ELISA method. NBT method was used to detect the differentiation of APL cells at the same time. Results: 96 h after exposure to ATRA at 10-6 M in vitro or 60 mg/day in vivo, APL cells showed a significant increase of IL-1b (P<0.05) and G-CSF (P<0.05) production, and a significant decrease of IL-6 (P<0.05) and IL-8 (P<0.05), however, there was no obvious variation of TNFa. On the other hand, the proliferation of APL cells in vitro was statistically correlated to the IL-1b secretion or G-CSF secretion. And the cell number ratio in patients with detectable IL-1b or G-CSF was higher than that without detectable IL-1b or G-CSF. Conclusion: IL-1b and G-CSF secretion may play an important role in the proliferation of APL cells after exposure to ATRA. 展开更多
关键词 CYTOKINE acute promyelocytic leukemia All-trans retinoic acid
下载PDF
Status epilepticus and acute promyelocytic leukemia
16
作者 Sunil Kumar Garg Pragya Garg 《Journal of Acute Disease》 2017年第5期235-236,共2页
Neurological manifestations are rare as initial presentation in acute promyelocytic leukemia (APL). This case illustrates status epilepticus as initial presentation in this disease. Atypical cells on peripheral smear ... Neurological manifestations are rare as initial presentation in acute promyelocytic leukemia (APL). This case illustrates status epilepticus as initial presentation in this disease. Atypical cells on peripheral smear led to the diagnosis of leukemia. 展开更多
关键词 acute promyelocytic leukemia acute STROKE STATUS epilepticus ATYPICAL cells
下载PDF
COMPARISON OF CLINICAL OBSERVATIONS BETWEEN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA TREATED WITH ALL-TRANS RETINOIC ACID AND CHEMOTHERAPY
17
作者 张芬琴 吴立德 +3 位作者 李秀松 孙关林 蔡敬仁 王振义 《Medical Bulletin of Shanghai Jiaotong University》 CAS 1992年第2期83-87,共5页
Clinical observations were retrospectively compared between 2 matched groups of patients with acute promyelocytic leukemia (APL) each 20. The first group were treated with chemotherapy, the other with all-tram retinoi... Clinical observations were retrospectively compared between 2 matched groups of patients with acute promyelocytic leukemia (APL) each 20. The first group were treated with chemotherapy, the other with all-tram retinoic acid (ATRA) alone at a dose of 45-60mg/M^2/d. The complete remission (CR) rate of ATRA group was significantly higher than that of chemotherapy (90% vs 55%). The time for obtaining CR as well as the duration of fever and hospitalization were shorter and the amount of blood transfused was less in the former than in the latter group. Seven cases were complicated by DIC and 4 died in the group of chemotherapy, while no case was by of DIC or death in the ATRA group. The mechanism was discussed. ATRA is an alternative effective drug for remission induction therapy in APL with high rate of CR. 展开更多
关键词 acute promyelocytic leukemia ALL-TRANS RETINOIC acid complete REMISSION rate
下载PDF
Pediatric acute myeloid leukemia patients with i(17)(q10)mimicking acute promyelocytic leukemia:Two case reports
18
作者 Hong-Xia Yan Wei-Hua Zhang +3 位作者 Jin-Quan Wen Yan-He Liu Bao-Juan Zhang A-Duo Ji 《World Journal of Clinical Cases》 SCIE 2022年第16期5446-5455,共10页
BACKGROUND Chromosome i(17)(q10)abnormality is mainly associated with chronic myeloid leukemia(CML),myelodysplastic syndrome/myeloproliferative tumors(MDS/MPD),and acute myeloid leukemia(AML).The role of i(17)(q10)in ... BACKGROUND Chromosome i(17)(q10)abnormality is mainly associated with chronic myeloid leukemia(CML),myelodysplastic syndrome/myeloproliferative tumors(MDS/MPD),and acute myeloid leukemia(AML).The role of i(17)(q10)in AML is still unknown,the differences between AML and acute promyelocytic leukemia(APL)-like AML with i(17)(q10)need more research.This study aimed to investigate the clinical characteristics and laboratory evidence of 2 AML cases with i(17)(q10),similar to APL phenotype.CASE SUMMARY Both pediatric patients were males;case 1 had newly diagnosed AML,and case 2 showed relapsed tumor after 1 year of drug withdrawal.Bone marrow cell morphology,chromosome karyotype analysis,Fully-instrumented submersible housing test,immunological assays,molecular biological methods,and blood tumor panoramic gene test were performed.All-trans retinoic acid(ATRA)combined with arsenic acid(As2O3)were used in the first course of treatment.Bone marrow was dominated by abnormal promyelocytic granulocytes.Karyotype test revealed i(17)(q10)isochromosome.Immunological phenotype mainly included positive expressions of CD9,CD13,CD33,and CD38.Case 1 suffered intracranial hemorrhage after re-chemotherapy and died on D162.For case 2,on D145 and D265,bone marrow promyelocytic granulocytes accounted for 2%.Flow cytometric residual lesion detection showed no abnormal immunophenotype cells.The copy number of WT1 gene in two cases were 1087 and 1010,respectively,and the expression rates were 55.29% and 59.5%,respectively.CONCLUSION ATRA,As2O3,and chemotherapy may be ineffective in treating APL-like AML with i(17)(q10)but without t(15;17)and PML-RARA fusion gene. 展开更多
关键词 CHROMOSOME i(17)(q10) Gene mutations acute promyelocytic leukemia acute myeloid leukemia Case report
下载PDF
Oral manifestations of acute promyelocytic leukemia: A case report
19
作者 Daisuke Saito Daisuke Saito Tadaharu Kobayashi +3 位作者 Yohei Oda Kanae Niimi Hiroyuki Kano Chikara Saito 《Open Journal of Stomatology》 2013年第1期25-27,共3页
Acute?leukemia?is?often?associated?with?oral?manifestations.?We?report?an?acute?promyelocytic?leukemia?(APL)?case?with?oral?manifestations?leading?to?the?diagnosis. A?21-year-old?female visited?our?hospital?with?compl... Acute?leukemia?is?often?associated?with?oral?manifestations.?We?report?an?acute?promyelocytic?leukemia?(APL)?case?with?oral?manifestations?leading?to?the?diagnosis. A?21-year-old?female visited?our?hospital?with?complaints?of?gingival?bleeding?and?swelling?of?the?left?lower?wisdom?tooth.?The?patient’s?complete?blood?count?revealed?a?marked?increase?in?white?blood?cells?and?a?decrease?in?red?blood?cells?and?an?abnormal?leukocyte?differential,?and APL?was?diagnosed?on?the?basis?of?bone?marrow?samples in?the internal?medicine?department.?The?patient?was?treated?with?all-trans-retinoic?acid combined?with?chemotherapy?and?has?maintained?clinical?and?molecular?complete?remission?at?12?months?of?follow-up. Dental?professionals should?be?aware?of?clinical?manifestations?and?complications?associated?with these?malign-nant?neoplastic?diseases?to?aid?in?diagnosis?and?subsequent?treatment?and?management. 展开更多
关键词 acute promyelocytic leukemia OralManifestations ORAL CARE
下载PDF
Therapy-related acute promyelocytic leukemia with FMS-like tyrosine kinase 3-internal tandem duplication mutation in solitary bone plasmacytoma: A case report
20
作者 Li-Li Hong Xian-Fu Sheng Hai-Feng Zhuang 《World Journal of Clinical Cases》 SCIE 2020年第19期4579-4587,共9页
BACKGROUND Therapy-related acute promyelocytic leukemia(t-APL)is a rare complication observed in solitary bone plasmacytoma(SBP),and SBP after radiotherapy evolving to APL harboring the FMS-like tyrosine kinase 3-inte... BACKGROUND Therapy-related acute promyelocytic leukemia(t-APL)is a rare complication observed in solitary bone plasmacytoma(SBP),and SBP after radiotherapy evolving to APL harboring the FMS-like tyrosine kinase 3-internal tandem duplication(FLT3-ITD)mutation has never been reported.Here,we present the first case reported until now.CASE SUMMARY We describe a 64-year-old woman who presented with lumbar pain and was initially diagnosed with SBP.However,after one year of radiotherapy treatment,this patient experienced a long-standing bone-marrow-suppressive period and finally developed APL harboring the FLT3-ITD mutation,as confirmed by analyses of clinical features,bone marrow morphology,flow cytometry,cytogenetic examination,and molecular biology.On admission,the patient had disseminated intravascular coagulation and intracranial hemorrhage,and the peripheral blood and bone marrow smear displayed abundant abnormal promyelocytes.Unfortunately,she died when the definite diagnosis was made.CONCLUSION The patient with t-APL harboring FLT3-ITD mutation evolving from SBP after radiotherapy had not been reported and had poor clinical outcomes.FLT3-ITD mutation in t-APL may be a potential pathogenesis of leukemogenesis.We should consider the potential risk of secondary neoplasms in SBP patients after radiotherapy. 展开更多
关键词 Solitary bone plasmacytoma Therapy-related acute promyelocytic leukemia FMS-like tyrosine kinase 3-internal tandem duplication mutation Radiotherapy Cytopenia Disseminated intravascular coagulation Case report
下载PDF
上一页 1 2 57 下一页 到第
使用帮助 返回顶部